Procter & Gamble Health

    PGHL
    Pharma
    ₹5,505.00
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹9,138 Cr

    P/E
    26.26
    Day range
    ₹5,360.50 – ₹5,543.50
    52-week range
    ₹4,707.00 – ₹6,975.00
    Volume
    21,566
    Open
    ₹5,501.50
    Prev close
    ₹5,464.50

    Latest results · Q2 FY27(standalone)Revenue ₹382 Cr+17.7%Profit ₹112 Cr+25.9%Margin 29.2%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 76 / 100

    Factor percentiles

    Value—
    Quality94
    Momentum48
    Low volatility85

    Derived metrics

    Earn. yield
    3.8%
    12-1 mom.
    -12.5%
    Return / vol
    -0.28
    Magic Formula
    #41

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Procter & Gamble HealthPGHL₹9,138 Cr26.26—61.6%84.0%40.0%0.01+17.5%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 2h ago

    Headlines about Procter & Gamble Health from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    ROE (FY26)
    61.6%
    ROCE (latest year)
    84%

    Moving averages (NSE)

    20-day
    ₹5,524.98
    Price below
    50-day
    ₹5,444.37
    Price above
    200-day
    ₹5,592.34
    Price below

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +4.6%
    Profit 3Y CAGR
    +12.6%
    Revenue YoY (Sep 2026 (S))
    +17.5%
    Profit YoY (Sep 2026 (S))
    +25.8%
    Operating margin
    40.0%
    Net margin
    29.3%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr100 Cr200 Cr300 Cr400 Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023 (S)Jun 2024 (S)Dec 2024 (S)Jun 2025 (S)Dec 2025 (S)Sep 2026 (S)0%20%40%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • DII
    • FII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Dec 2018 (S)Jun 2020 (S)Jun 2022 (S)Jun 2024 (S)Mar 2026 (S)-1K Cr0 Cr1K Cr2K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%20%40%60%80%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr500 Cr1K Cr1.5K Cr2K Cr
    • Equity
    • Debt

    Debt to equity

    Dec 2019 (S)Jun 2021 (S)Jun 2023 (S)Mar 2025 (S)Sep 2026 (S)0x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY18FY19FY20FY21FY22FY23FY24FY25FY26FY27₹0₹200₹400₹600

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023 (S)Mar 2024 (S)Jun 2024 (S)Sep 2024 (S)Dec 2024 (S)Mar 2025 (S)Jun 2025 (S)Sep 2025 (S)Dec 2025 (S)Mar 2026 (S)Jun 2026 (S)Sep 2026 (S)
    Sales310252284313310311339325374370364382
    YoY Sales growth—-21-6—0———————
    Expenses208185236199186230248205263235264230
    Operating Profit10267481141238190120110136100152
    OPM %33%27%17%36%40%26%27%37%30%37%27%40%
    Other Income52-183434544364
    Interest000000000000
    Depreciation777665566666
    Profit before tax10063231111227989119109133129150
    Tax %28%26%26%26%25%22%25%26%29%29%26%26%
    Net Profit7247178291616689789596112
    EPS in Rs₹43.42₹28.05₹10.11₹49.60₹54.76₹36.86₹39.87₹53.34₹46.74₹56.99₹57.92₹67.18

    From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days43

    +21 days since Jun 2021 (S)

    Inventory Days137

    -1 days since Jun 2021 (S)

    Days Payable192

    -17 days since Jun 2021 (S)

    Cash Conversion Cycle-13

    +36 days since Jun 2021 (S)

    Working Capital Days30

    +23 days since Jun 2021 (S)

    Strengths, risks & growth

    Procter & Gamble Health Ltd, formerly Merck Ltd, manufactures and markets vitamins, minerals, supplements and other healthcare products under brands including Neurobion, Livogen, Seven Seas, Evion, Polybion and Nasivion. It is part of the US-based P&G Group and operates a plant at Usgaon, Goa [1]

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter51.82%51.82%51.82%51.82%0.00 pp
    FII6.97%6.20%6.33%6.43%+0.10 pp
    DII13.84%13.67%12.44%12.63%+0.19 pp
    Public27.37%28.30%29.41%29.13%-0.28 pp

    Filed with NSE for Sept 2026: promoters 51.82%, public 48.18%

    Analysts & fund holdings

    100%
    100% recommend buy
    1 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E26.3 vs 45.1
    Sector P/B6.03
    Beta0.27

    Who holds the shares, quarter by quarter

    Mutual funds 8.89% (-0.16 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters51.8%
    • Foreign institutions6.4%
    • Mutual funds8.9%
    • Insurance3.6%
    • Other domestic institutions0.1%
    • Retail21.5%
    • Others7.6%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Nippon India Small Cap Fund4.34%0.51%-0.07 pp
    UTI MNC Fund1.19%4.25%-0.29 pp
    DSP Healthcare Fund1.00%2.42%-0.47 pp
    Aditya Birla SL MNC Fund0.59%1.87%-0.03 pp
    Tata India Pharma & Healthcare Fund0.52%3.15%+0.73 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    26.1%
    Downside volatility
    24.7%
    Worst 5% of days
    2.4%
    Average of that tail
    3.5%
    Max drawdown (1Y)
    27.5%
    Below its peak
    20.4%

    Against the market

    Beta vs Nifty 50
    0.47
    Correlation
    0.25
    Relative strength (3M)
    -9.6%
    ATR (14)
    3.7%

    Return

    Return 1M
    +5.9%
    Return 3M
    -5.7%
    Return 6M
    +4.8%
    Return 1Y
    -7.3%
    vs 200-day average
    -1.6%

    Momentum

    RSI (14)
    48.6
    MACD histogram
    -9.64
    Stochastic %K
    21.4
    ADX (14)
    28.2
    +DI / −DI
    25.1 / 22.0
    Money flow index
    62.2

    Participation

    Delivery (20d avg)
    52.9%
    vs its 60-day baseline
    -1.9 pts
    Volume vs 20-day
    +0.4σ
    Close vs day's VWAP
    +1.4%
    52-week position
    34 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Corporate actions

    • dividend
      ₹45.00

      Dividend - Rs 45 Per Share

      27 Aug 2026
      ex-date
    • dividend
      ₹110.00

      Interim Dividend - Rs 110 Per Share & Special Dividend Rs 50 Per Share

      12 Feb 2026
      ex-date
    • dividend
      ₹45.00

      Dividend - Rs 45 Per Share

      22 Aug 2025
      ex-date
    • dividend
      ₹80.00

      Interim Dividend - Rs 80 Per Share

      21 Feb 2025
      ex-date
    • dividend
      ₹60.00

      Annual General Meeting/Dividend - Rs 60 Per Share

      28 Nov 2024
      ex-date
    • dividend
      ₹50.00

      Interim Dividend - Rs 50 Per Share & Special Dividend Rs 150 Per Share

      14 Feb 2024
      ex-date
    • dividend
      ₹50.00

      Annual General Meeting/Dividend - Rs 50 Per Share

      23 Nov 2023
      ex-date
    • dividend
      ₹45.00

      Interim Dividend - Rs 45 Per Share

      13 Feb 2023
      ex-date
    • dividend
      ₹11.50

      Annual General Meeting/Dividend - Rs 11.50 Per Share

      15 Nov 2022
      ex-date
    • dividend
      ₹41.00

      Interim Dividend - Rs 41 Per Share

      12 May 2022
      ex-date
    • dividend
      ₹40.00

      Annual General Meeting/Dividend - Rs 40 Per Share/Special Dividend - Rs 90 Per Share

      2 Nov 2021
      ex-date
    • dividend
      ₹42.00

      Annual General Meeting/Dividend - Rs 42 Per Share Special Dividend - Rs 188 Per Share

      18 Nov 2020
      ex-date
    • dividend
      ₹416.00

      Annual General Meeting / Special Dividend - Rs 416 Per Share/ Final Dividend - Rs 24 Per Share

      23 May 2019
      ex-date
    • dividend
      ₹15.00

      Annual General Meeting/ Dividend - Rs 15 Per Share

      21 May 2018
      ex-date
    • dividend
      ₹11.00

      Annual General Meeting/Dividend-Rs 11/- Per Share (Revised)

      25 May 2017
      ex-date
    • dividend
      ₹7.50

      Annual General Meeting/Dividend - Rs 7.50/- Per Share (Book Closure Dates Revised)

      22 Apr 2016
      ex-date
    • dividend
      ₹6.00

      Annual General Meeting / Dividend - Rs 6/- Per Share

      30 Mar 2015
      ex-date
    • dividend
      ₹8.50

      Annual General Meeting/Dividend - Rs 8.50/- Per Share

      10 Mar 2014
      ex-date
    • dividend
      ₹2.50

      Annual General Meeting/Dividend Rs 2.50 Per Share

      7 Mar 2013
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      27 Mar 2012
      ex-date

    Company announcements

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Please find attached signed Certifiacte for confirming compliance under Regulation 74(5) of the SEBI (DP) Regulations, for the quarter ended September 30, 2026.

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Intimation Of Board Meeting

    Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve unaudited financial ....

    Insider Trading / SAST
    Closure of Trading Window

    We would like to inform you that the Trading Window of the Company shall remain closed for the Directors and Designated Employees from October 1, 2026 until 48 hours from the publication ....

    Company Update
    Intimation Regarding Ease Of Doing Investment - Special Window For Transfer And Dematerialization

    Stock Exchange is informed about an update on Ease of doing Investment - Special Window for Transfer and Dematerialization.

    Company Update
    Re-Appointment Of Mr. S. Madhavan As Independent Director Of The Company.

    The shareholders at their AGM held on September 3, 2026 approved the re-appointment of Mr. S. Madhavan as Independent Director of the Company for a period of 5 years effective November 15, 2026.

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Scrutinizers Report and E-Voting results for the Annual General Meeting held on September 3, 2026.

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Enclosed a summary of proceedings of the Annual General Meeting held today, viz., September 3, 2026.

    AGM/EGMPrice-sensitive
    59Th Annual General Meeting Of The Company

    The 59th Annual General Meeting of the Company is scheduled on Thursday, September 3, 2026 at 2:30 PM.

    Others
    Business Responsibility and Sustainability Reporting (BRSR)

    The BRSR Report for the Financial Year ended March 31, 2026 is enclosed.

    Others
    Reg. 34 (1) Annual Report.

    Annual Report for the Financial Year 2025-26 is enclosed for the Annual General Meeting scheduled on Thursday September 3, 2026.

    AGM/EGMPrice-sensitive
    Notice Calling The 59Th Annual General Meeting Of The Company.

    Enclosed herewith is the Annual Report for the Financial Year 2025-26 and Notice calling the 59th Annual General Meeting of the Company, scheduled on Thursday, September 3, 2026 at 2:30 p.m.

    Corp. Action
    Record Date For Purpose Of Dividend

    Record Date for Purpose of Dividend

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Press Release on the Unaudited Financial Results for the Quarter ended June 30, 2026.

    Result
    Unaudited Financial Results For The Quarter Ended June 30, 2026

    Unaudited Financial Results for the Quarter ended June 30, 2026

    Board Meeting
    Board Meeting Outcome for Outcome Of Board Meeting

    Outcome of Board Meeting.

    Filed with BSE (scrip 500126); the last 45 days. Documents open at bseindia.com.

    Documents

    Earnings calls

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 3 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Procter & Gamble Health: common questions

    Answered from the figures on this page.

    Procter & Gamble Health last traded at ₹5,505.00 (NSE, as of 18 Nov 2026). The last session moved it up 0.74%.

    Procter & Gamble Health is valued at about ₹9,138 crore (NSE, as of 18 Nov 2026).

    Procter & Gamble Health trades at a price-to-earnings ratio of 26.26 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Procter & Gamble Health has traded between ₹4,707.00 and ₹6,975.00 over the past 52 weeks, to 18 Nov 2026. It is currently 35% of the way up that range.

    Procter & Gamble Health (PGHL) is classified under Pharma on this site's screener.